ClinicalTrials.gg
Active, not recruitingNCT04805814CorCMRUpdated Nov 18, 2026

Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) Trial

An interventional study of CMR results disclosed and CMR performed but results not disclosed in Microvascular Angina, Angina Pectoris and Angina, Stable, sponsored by NHS National Waiting Times Centre Board. Active, not recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by NHS National Waiting Times Centre Board · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 18, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Microvascular Angina with a site in United Kingdom — 6 open to participants now, 12 under way, none of them phase 3. Microvascular Angina · United Kingdom.

Planned enrollment
2nd of 12
280 · median 59
Started
2021
with 1 other
No phase
9 of 18
1 open now
Primary completion
2024-10
later than 1 of 11 live
Registered
9th of 18
by date
Lead sponsor
4 of 18
NHS National Waiting Times Centre Board

Among the 18 studies in Microvascular Angina with a site in United Kingdom, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 9 with no phase, reaches primary completion later than 1 of the 11 other live ones, and was the 9th registered.

Microvascular Angina

111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.

Browse Microvascular Angina studies →

Open to participants now

6 of the 18 studies in Microvascular Angina with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Microvascular Angina with a site in United Kingdom, or all of them as a file.
02

Study summary

Anginal symptoms due to ischaemia with no obstructive coronary arteries (INOCA) is a common clinical problem, however, diagnosis and onward management is heterogeneous, and prognosis is affected. Recent advances in quantifying myocardial blood flow using stress perfusion cardiac magnetic resonance imaging (CMR) has potential for accurate detection coronary microvascular dysfunction.

The CorCMR diagnostic study involves stress perfusion CMR in patients with suspected INOCA to clarify the prevalence of subgroups of patients with underlying problems, such as microvascular disease or undisclosed obstructive coronary artery disease, that might explain their anginal symptoms.

A nested, prospective, randomised, controlled, double-blind trial will determine whether stratified medical therapy guided by the results of the stress perfusion CMR improves symptoms, well-being, cardiovascular risk and health and economic outcomes.

Read the detailed description

Background:

There are approximately 2 million men and women living with angina in the UK. In 2014, there were \~247,000 coronary angiograms performed, mostly for the investigation of known or suspected angina. However, obstructive CAD is detected in only 1 in 2 patients. The explanation for the cause(s) of the chest pain are often unclear. Microvascular or vasospastic angina may be one explanation.

Adjunctive tests of coronary artery function to diagnose these problems are rarely used during coronary angiography in the NHS, meaning that patient management may be empirical and heterogeneous. The lack of adoption of these novel tests in the NHS reflects key gaps in the clinical evidence. It is these gaps, coupled with the increasing adoption of anatomical coronary artery imaging with CT coronary angiography (CTCA), which stimulate this research. In recent large clinical trials, CT coronary angiography has been shown not to reduce the rate of invasive angiography. In fact, compared to standard care based on stress testing, CTCA is associated with less improvement in anginal symptoms and in quality of life (PUBMED ID: 28246175). Anatomical tests, such as CTCA and invasive angiography, do not provide information on myocardial blood flow. New evidence that addresses these gaps might inform therapy development and future trials.

Current gaps in evidence and guidelines point to a problem of unmet need in the NHS care pathway. Stress perfusion CMR has potential diagnostic value for microvascular disease, but whether it might discriminate clinical endotypes in a relatively unselected population of patients in daily practice, is uncertain. Further, access to stress perfusion CMR varies widely not least because evidence from randomised trials supporting clinical and economic benefits from a CMR-guided approach is lacking. CorCMR is a clinical strategy trial that is designed to address this evidence gap.

Hypothesis:

In patients with angina in whom obstructive disease in the epicardial coronary arteries has been ruled out by coronary angiography ± FFR, stress perfusion CMR will reclassify the diagnosis leading to changes in treatment (start or stop therapy), improvements in health and economic outcomes, as compared to decisions based standard care (CMR not disclosed).

Design:

We propose that an observational, diagnostic study involving stress CMR will provide information on the prevalence of microvascular disease in a population with anginal symptoms potentially attributable to myocardial ischaemia with no obstructive coronary arteries (INOCA). Each diagnosis is linked to a guideline-directed treatment plan.The potential value of this strategy can only be confirmed if it is associated with patient benefits, which is why we propose a nested, randomised, controlled, double-blind trial of routine disclosure of stress perfusion CMR vs. angiography-guided management

Methods:

Patients undergoing invasive coronary angiography for the investigation of known or suspected angina and who do not have either structural heart disease or a systemic health problem that would explain those symptoms will be invited to participate. Written informed consent is required for participation. Eligibility is further confirmed at the time of the coronary angiogram by exclusion of obstructive (stenosis >70% in a single segment or 50 - 70% in 2 adjacent segments in an artery >2.5 mm, or FFR ≤0.80) coronary artery disease (CAD). Angina symptoms will be confirmed by the completion of validated questionnaires and patients will be invited to attend for a stress perfusion CMR within 3 months of the original coronary angiogram.

On arrival for the CMR, patients will be randomised (1:1) to either the intervention (CMR guided, results disclosed) or blinded control group (CMR undertaken but results not disclosed, standard of care) group.

Trial participants will be blinded to treatment group. The clinicians responsible for on-going care will also be blinded. The design is therefore 'double-blind'. Following the CMR, patients and clinicians will be advised of the diagnosis (endotype) but not the randomised group. The endotype will be informed by the CMR in the intervention group but not in the control group (CMR results not disclosed, angiography-guided). Medical therapy and lifestyle measures are linked to the endotype and informed by contemporary practice guidelines. Therefore, optimal guideline-directed medical care according to the endotype is intended to be the same, regardless of the group allocation.

The sample size is 280 randomised participants. The minimum follow-up duration is 12 months from the last participant recruitment. Follow-up will continued in the longer term including, where feasible, electronic case record linkage.

The primary outcome of the diagnostic study is the reclassification of the initial diagnosis based on findings from the cardiac MRI scan. The primary outcome of the nested randomised trial is the within-subject change at 6 months from baseline for the domains of the Seattle Angina Questionnaire.

Secondary outcomes include other Patient Reported Outcome Measures (PROMS) to describe other aspects of health and wellbeing. These include EQ-5D-5L, Illness perception (Brief IPQ), Treatment satisfaction (TSQM), Duke Activity Status Index (DASI), the International Physical Activity Questionnaire (IPAQ-SF) short-form and a pain questionnaire.

There is preliminary evidence that small vessel disease can be a systemic problem affecting different organs. Whether small vessel disease in the heart might associate with small vessel disease in the brain or retina is unknown. In the CorMicA pilot study, studies of small vessels isolated from biopsies found evidence of endothelial dysfunction and increased responsiveness of the blood vessels to naturally-occurring, constriction-inducing peptides such as endothelin and thromboxane. For these reasons, we plan heart-brain-retina and peripheral vascular substudies.

03

Conditions studied

  • Microvascular Angina
  • Angina Pectoris
  • Angina, Stable
  • Non-Obstructive Coronary Atherosclerosis
  • Small Vessel Cerebrovascular Disease
  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Symptoms of angina or angina-equivalent informed by the Rose Angina questionnaire.
  3. Coronary angiography ≤3 months with a plan for medical management.

Exclusion criteria

Exclusion Criteria:

  1. Obstructive coronary artery disease i.e. a stenosis >70% in a single segment or 50 - 70% in 2 adjacent segments in an artery >2.5 mm, or FFR ≤0.80.
  2. Coronary revascularization by percutaneous coronary intervention or coronary artery bypass graft surgery following the index angiogram.
  3. Prior coronary artery bypass surgery
  4. A diagnosis that would explain the angina e.g. anaemia, aortic stenosis, hypertrophic cardiomyopathy,
  5. to contrast-enhanced CMR e.g. \< 30mL/min/1.73m2.
  6. Contra-indication to intravenous adenosine, i.e. severe asthma; long syndrome; second- or third-degree AV block and sick sinus syndrome.
  7. Lack of .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Active comparator
    Intervention Group

    All randomised participants will receive stratified medicine. The subjects will undergo stress perfusion CMR as an adjunct to invasive coronary angiography. The CMR results will be disclosed to the clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and CMR findings.

    Diagnostic Test: CMR results disclosed

  • Sham comparator
    Standard Care Group

    All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also undergo stress perfusion CMR but the results will not be disclosed. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and CMR findings.

    Diagnostic Test: CMR performed but results not disclosed

Interventions

  • Diagnostic testCMR results disclosed

    The results of the CMR are disclosed, and used to guide management

  • Diagnostic testCMR performed but results not disclosed

    The results of the CMR are not disclosed, and management is angiography-guided

06

What researchers measure

Primary outcomes

  1. Reclassification of the initial diagnosis

    The reclassification of the initial diagnosis based on invasive management following multi-parametric stress perfusion CMR. The diagnostic groups (endotypes) are: 1. Anginal symptoms with a myocardial perfusion defect indicative of obstructive CAD; 2. Anginal symptoms associated with a myocardial perfusion defect indicative of microvascular disease; 3. Vasospastic angina; 4. Incidental finding that is actionable e.g. aortic stenosis, cardiomyopathy, lung cancer; or 5. No clinically significant finding or normal.

    Time frame: Day 1

  2. Seattle Angina Questionnaire (SAQ) Summary Score

    The 7-item version of the SAQ reflects the frequency of angina (SAQ Angina Frequency score) and the disease-specific effect of angina on patients' physical function (SAQ Physical Limitation score) and quality of life (Quality of Life score) over the previous 4 weeks; these scores are averaged to obtain the SAQ Summary score, which is an overall measure of patients' stable ischaemic heart disease-specific health status. SAQ scores range from 0 to 100, with higher scores indicating less frequent angina, improved function, and better quality of life.

    Time frame: 6 months

Secondary outcomes

  1. Compliance with the protocol

    Assess feasibility of the clinical strategy by measuring compliance with the protocol and, specifically, rate of enrolment, % of patients who drop-out, % of patients who complete the diagnostic MRI protocol.

    Time frame: 0-36 months

  2. Integrity of blinding in the Radiology Department and during follow-up

    Assess the integrity and feasibility of blinding by administering patient and clinician questionnaires to determine if both groups have been successfully blinded

    Time frame: 0-36 months

  3. Diagnostic utility

    To assess % of patients with a change in diagnosis following disclosure of the cardiac MRI results, and relatedly, the level of certainty reported by the physicians for the diagnosis (diagnostic utility). This will be assessed by a questionnaire completed by the clinician before the MRI, and then again after the MRI results are disclosed.

    Time frame: 0-36 months

  4. Clinical Utility

    To assess impact of disclosure of the cardiac MRI results on clinical management (including treatment and investigations). This will be measured by asking clinicians to complete a questionnaire on ongoing clinical management following disclosure of the MRI result

    Time frame: 0-36 months

  5. Abnormal myocardial perfusion

    Assess the prevalence of abnormal blood flow in the heart muscle, as defined by a minimum of 2 adjacent cardiac segments each with ≥50% deficit in myocardial perfusion at peak stress revealed by (1) visual assessment of the dynamic stress perfusion CMR scan and (2) pixel mapping of myocardial blood flow (\< 2.0 ml/min/g tissue).

    Time frame: Day 1

  6. Myocardial blood flow

    Assess the associations between myocardial blood flow (ml/min/g) and invasive measures of coronary function (where available) that might be implicated in the pathophysiology of abnormal coronary vascular function.

    Time frame: Day 1

  7. Myocardial tissue characteristics

    Assess the correlation between myocardial blood flow (ml/min/g) and myocardial tissue characteristics as revealed by MRI T1- and T2- relaxation times (ms) and extracellular volume fraction.

    Time frame: Day 1

  8. Cardiovascular risk

    Assess the correlation between cardiovascular risk factors, reflected by validated risk scores (e.g. ASSIGN, JBS3), and myocardial blood flow (ml/min/g) in medically managed patients.

    Time frame: Day 1

  9. Within subject change in myocardial blood flow

    Assess the within-subject change in cardiac MRI findings during 12-months. This will be done by measuring the within-subject change in peak, global, myocardial blood flow over 12 months.

    Time frame: 0-12 months

  10. Between-group, within subject change in myocardial blood flow

    Assess the between-group, within-subject change in cardiac MRI findings over 12 months. This outcome will provide insights into the effect of the study intervention on MRI findings. This will be done by measuring the within-subject, between group change in peak, global, myocardial blood flow over 12 months.

    Time frame: 0-12 months

  11. Health Status: EQ5D-5L Questionnaire

    The 5-item EuroQol Group EQ5D-5L is a validated questionnaire comprising mobility, self-care, usual activities, pain/discomfort and anxiety/depression to quantitatively assess patient's self-reported health status and will be administered at each study visit.

    Time frame: 0-36 months

  12. Health Status: Seattle Angina Questionnaire

    Seattle Angina Questionnaire (SAQ) Summary Score and component scores (Angina Limitation, Angina Stability, Angina Frequency, Treatment Satisfaction and Quality of Life) will be recorded at all study visits.

    Time frame: 0-36 months

  13. Health Status: Illness Perception - Brief IPQ

    Brief Illness Perception Questionnaire (Brief IPQ), a nine-item scale designed to rapidly assess the cognitive and emotional representations of illness taken at all study visits.

    Time frame: 0-36 months

  14. Health Status: Treatment satisfaction - TSQM

    The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) is a reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction and will administered at all study visits.

    Time frame: 0-36 months

  15. Health Status: Duke Activity Status Index

    The 12 point Duke Activity Status Index (DASI) is a validated questionnaire to assess functional capacity and will be administered at all study visits.

    Time frame: 0-36 months

  16. Health Status: International Physical Activity Questionnaire- Short Form (IPAQ-SF)

    The 4 point IPAQ-SF is a validated questionnaire to assess functional ability and activuty levels and will be administered at all study visits.

    Time frame: 0-36 months

  17. Health Status: Montreal Cognitive Assessment (MOCA)

    The MOCA is an internationally validated 30 point assessment of cognitive function, and will be administered on all study visits.

    Time frame: 0-36 months

  18. Correlation between myocardial blood flow and health status

    Assess the correlation between myocardial blood flow (ml/min/g) and health status, as measured by validated questionnaires.

    Time frame: 0-36 months

  19. Long term prognosis

    Assess the long-term prognostic significance of between myocardial perfusion (ml/min/g).

    Time frame: 0-20 years

  20. Health Outcomes: Major Adverse Cardiovascular Events

    MACE including death, re-hospitalisation for cardiovascular events including myocardial infarction, heart failure, stroke/ TIA, unstable angina and coronary revascularisation. Unscheduled hospital visits for chest pain that have not led to hospital admission will also be documented.

    Time frame: 0-20 years

  21. Angina events

    Anginal episodes based on completion of a chest symptoms log and adjudicated by a clinical event committee.

    Time frame: 0-3 years

  22. Brain small vessel disease

    Quantify small vessel disease score in the brain using the The STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) guidelines.

    Time frame: 0-36 months

  23. Correlation between small vessel disease in the brain and myocardial perfusion

    Assess the correlation between MRI features of small vessel disease in the brain and myocardial perfusion.

    Time frame: 0-36 months

  24. Health economics: Inpatients visits

    Health resource utilisation will also be assessed by recording the number of inpatient visits in the follow-up period

    Time frame: 0-20 years

  25. Health economics: Cardiac procedures

    Health resource utilisation will also be assessed by recording the number of repeat cardiac procedures performed in the follow up period

    Time frame: 0-20 years

  26. Health economics: Medication use

    Health resource utilisation will also be assessed by recording the medication used in the follow up period

    Time frame: 0-20 years

  27. Work limitation

    Use the 8-item Work limitation Questionnaire to estimate productivity loss and time lost from work, where appropriate.

    Time frame: 0-36 months

Other outcomes

  1. Small vessel substudy

    Sub-study of small vessel function using myography in arterioles isolated from gluteal skin biopsies. Standard pharmacological read-outs include the drug concentration required to achieve 50% of the maximum contraction and/or relaxation (wire myography) and structure/function relationships (pressure myography).

    Time frame: 0-12 months

  2. Retinal imaging substudy

    Retinal vascular imaging by optical coherence tomography (OCT) to assess for the presence or absence of small vessel disease.

    Time frame: 0-12 months

07

Study locations

3 sites
08

References and documents

Publications

  • Bradley CP, Orchard V, Sykes RA, McKinley G, McConnachie A, Donnelly P, Watt J, Kellman P, Quinn T, Fullerton N, Berry C. Heart-brain microvascular MRI study: protocol for a multicentre, observational, cohort study in the UK assessing associations between small vessel disease of the heart and brain. BMJ Open. 2024 Dec 20;14(12):e088372. doi: 10.1136/bmjopen-2024-088372. PubMed 39806582 ↗
  • Bradley CP, Berry C. Microvascular arterial disease of the brain and the heart: a shared pathogenesis. QJM. 2023 Oct 23;116(10):829-834. doi: 10.1093/qjmed/hcad158. PubMed 37467080 ↗
  • Bradley CP, Orchard V, McKinley G, Heggie R, Wu O, Good R, Watkins S, Lindsay M, Eteiba H, McGowan J, McGeoch R, Corcoran D, Kellman P, McConnachie A, Berry C. The coronary microvascular angina cardiovascular magnetic resonance imaging trial: Rationale and design. Am Heart J. 2023 Nov;265:213-224. doi: 10.1016/j.ahj.2023.08.067. Epub 2023 Aug 30. PubMed 37657593 ↗
  • Bradley C, Berry C. Definition and epidemiology of coronary microvascular disease. J Nucl Cardiol. 2022 Aug;29(4):1763-1775. doi: 10.1007/s12350-022-02974-x. Epub 2022 May 9. PubMed 35534718 ↗
  • Sidik NP, Stanley B, Sykes R, Morrow AJ, Bradley CP, McDermott M, Ford TJ, Roditi G, Hargreaves A, Stobo D, Adams J, Byrne J, Mahrous A, Young R, Carrick D, McGeoch R, Corcoran D, Lang NN, Heggie R, Wu O, McEntegart MB, McConnachie A, Berry C. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial. Circulation. 2024 Jan 2;149(1):7-23. doi: 10.1161/CIRCULATIONAHA.123.064751. Epub 2023 Oct 5. PubMed 37795617 ↗
  • Ludman P on behalf of the British Cardiovascular Intervention Society (BCIS). BCIS Audit Returns for Adult Interventional Procedures (Jan - Dec 2016). October 2017. https://www.bcis.org.uk/resources/audit-results/
  • Williams MC, Hunter A, Shah A, Assi V, Lewis S, Mangion K, Berry C, Boon NA, Clark E, Flather M, Forbes J, McLean S, Roditi G, van Beek EJ, Timmis AD, Newby DE; Scottish COmputed Tomography of the HEART (SCOT-HEART) Trial Investigators. Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. Heart. 2017 Jul;103(13):995-1001. doi: 10.1136/heartjnl-2016-310129. Epub 2017 Feb 28. PubMed 28246175 ↗
  • Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, Eteiba H, Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E, Sidik N, McCartney P, Corcoran D, Collison D, Rush C, McConnachie A, Touyz RM, Oldroyd KG, Berry C. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2841-2855. doi: 10.1016/j.jacc.2018.09.006. Epub 2018 Sep 25. PubMed 30266608 ↗
  • Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, Watkins S, Eteiba H, Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E, McCartney P, Corcoran D, Collison D, Rush C, Sattar N, McConnachie A, Touyz RM, Oldroyd KG, Berry C. 1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC Cardiovasc Interv. 2020 Jan 13;13(1):33-45. doi: 10.1016/j.jcin.2019.11.001. Epub 2019 Nov 11. PubMed 31709984 ↗
  • Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, Prescott E, Karam N, Appelman Y, Fraccaro C, Buchanan GL, Manzo-Silberman S, Al-Lamee R, Regar E, Lansky A, Abbott JD, Badimon L, Duncker DJ, Mehran R, Capodanno D, Baumbach A. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention. 2021 Jan 20;16(13):1049-1069. doi: 10.4244/EIJY20M07_01. PubMed 32624456 ↗
  • Ford TJ, Berry C. Angina: contemporary diagnosis and management. Heart. 2020 Mar;106(5):387-398. doi: 10.1136/heartjnl-2018-314661. Epub 2020 Feb 12. No abstract available. PubMed 32054665 ↗
  • Corcoran D, Ford T, Hsu LY, Orchard V, Oldroyd KG, Arai AE, Berry C, on behalf of the CorMicA Investigators. The diagnostic utility of multiparametric CMR in patients with angina and non-obstructive coronary artery disease. Eur Heart J. 2020;
  • Kotecha T, Martinez-Naharro A, Boldrini M, Knight D, Hawkins P, Kalra S, Patel D, Coghlan G, Moon J, Plein S, Lockie T, Rakhit R, Patel N, Xue H, Kellman P, Fontana M. Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction: Validation Against Invasive Coronary Physiology. JACC Cardiovasc Imaging. 2019 Oct;12(10):1958-1969. doi: 10.1016/j.jcmg.2018.12.022. Epub 2019 Feb 13. PubMed 30772231 ↗
  • Hsu LY, Jacobs M, Benovoy M, Ta AD, Conn HM, Winkler S, Greve AM, Chen MY, Shanbhag SM, Bandettini WP, Arai AE. Diagnostic Performance of Fully Automated Pixel-Wise Quantitative Myocardial Perfusion Imaging by Cardiovascular Magnetic Resonance. JACC Cardiovasc Imaging. 2018 May;11(5):697-707. doi: 10.1016/j.jcmg.2018.01.005. Epub 2018 Feb 14. PubMed 29454767 ↗
  • Knott KD, Seraphim A, Augusto JB, Xue H, Chacko L, Aung N, Petersen SE, Cooper JA, Manisty C, Bhuva AN, Kotecha T, Bourantas CV, Davies RH, Brown LAE, Plein S, Fontana M, Kellman P, Moon JC. The Prognostic Significance of Quantitative Myocardial Perfusion: An Artificial Intelligence-Based Approach Using Perfusion Mapping. Circulation. 2020 Apr 21;141(16):1282-1291. doi: 10.1161/CIRCULATIONAHA.119.044666. Epub 2020 Feb 14. PubMed 32078380 ↗
  • Berry C, Sidik N, Pereira AC, Ford TJ, Touyz RM, Kaski JC, Hainsworth AH. Small-Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions. J Am Heart Assoc. 2019 Feb 5;8(3):e011104. doi: 10.1161/JAHA.118.011104. No abstract available. PubMed 30712442 ↗
  • Ford TJ, Rocchiccioli P, Good R, McEntegart M, Eteiba H, Watkins S, Shaukat A, Lindsay M, Robertson K, Hood S, Yii E, Sidik N, Harvey A, Montezano AC, Beattie E, Haddow L, Oldroyd KG, Touyz RM, Berry C. Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J. 2018 Dec 7;39(46):4086-4097. doi: 10.1093/eurheartj/ehy529. PubMed 30165438 ↗
  • Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Good R, Joshi F, Lindsay M, McCartney P, McGowan J, McGeoch R, Robertson KE, Rocchiccioli JP, Shaukat A, Watkins S, Kellman P, McConnachie A, Berry C. Non-invasive endotyping improves treatment satisfaction and prescribing appropriateness in patients with angina and no obstructive coronary artery disease. Open Heart. 2026 Apr 17;13(1):e004135. doi: 10.1136/openhrt-2026-004135. PubMed 41997615 ↗
  • Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Good R, Joshi F, Lindsay M, McCartney P, McGowan J, McGeoch R, Robertson K, Rocchiccioli P, Shaukat A, Watkins S, Kellman P, McConnachie A, Berry C. Endotype-informed therapy and effects on illness perception and psychological health in patients with chest pain and no obstructive coronary artery disease. Eur Heart J Qual Care Clin Outcomes. 2026 Sep 16;12(6):998-1008. doi: 10.1093/ehjqcco/qcag081. PubMed 42241125 ↗
  • Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Good R, Joshi F, Lindsay M, McCartney P, McGowan J, McGeoch R, Robertson K, Rocchiccioli P, Shaukat A, Watkins S, Kellman P, McConnachie A, Berry C. Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial. Nat Med. 2026 Jan;32(1):332-341. doi: 10.1038/s41591-025-04044-4. Epub 2025 Nov 10. PubMed 41214345 ↗

Individual participant data

Plan to share: Yes — Anonymised data may be shared based on a research agreement

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After the study has completed

Access criteria: Bone fide collaboration request

Data sharing details ↗ · www.gla.ac.uk

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2024, 43 months.

Of 24 interventional studies with no phase under Microvascular Angina, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 66. This study's 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2021
First posted
Mar 18, 2021
StartActual
Feb 9, 2021
Primary completionActual
Oct 1, 2024
CompletionEst.
Oct 1, 2034
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Goo… PubMed 41997615 ↗; 2 more
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Publications Results publication added: Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Goo… PubMed 41997615 ↗; 2 more
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04805814
Lead sponsor
NHS National Waiting Times Centre Board
Collaborators
University of Glasgow, British Heart Foundation, Chief Scientist Office of the Scottish Government
Responsible party
Colin Berry (Chief Investigator, NHS National Waiting Times Centre Board) — Principal investigator
First posted
Mar 18, 2021
Start date
Feb 9, 2021
Primary completion
Oct 1, 2024
Completion
Oct 1, 2034 (estimated)
Last update
Nov 18, 2026

Study contacts

Colin Berry, MBChB, PhD
principal investigator · Univerisity of Glasgow

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion